Alfa-TIL^TM Platform

Online Inquiry

* Your Name

* E-mail Address

Phone Number

Services Interested

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and therapeutic services for individuals.

Low-Input & Rapid TIL Isolation and Expansion

Tumor-Infiltrating Lymphocytes (TILs) are key immune components for targeting and eliminating cancer cells. Their therapeutic potential hinges on the ability to efficiently isolate and expand these cells from limited tumor samples. Traditional methods often require large amounts of tumor tissue and extended culture periods, which can be a bottleneck in preclinical development. Alfa-TIL^TM offers a next-generation solution for low-input & rapid TIL isolation and expansion, designed to optimize cell yield and quality with minimal tumor input. This service is ideal for early-stage drug discovery and cancer immunotherapy research, where quick turnaround times and small sample volumes are crucial.

Introduction to Efficient TIL Isolation in Preclinical Research

The success of preclinical TIL development depends on the ability to reliably isolate and expand functional lymphocytes from limited tumor samples. However, traditional TIL isolation workflows were originally designed for clinical-scale manufacturing and are often not optimized for the constraints of early-stage research—such as small tissue volume, tight timelines, or frequent iteration needs. For preclinical applications, an efficient and reproducible method for isolating TILs from minimal input is critical. Such a method must balance high yield and quality with operational simplicity and speed, while remaining adaptable to a variety of sample types including murine tumors, xenografts, and small human biopsies.

Fig. 1 General scheme of the preparation of TILs. (Zhao, Y., et al., 2022) Fig.1 Conventional TIL expansion and the development of NeoExpand for selective neoantigenic stimulation of TILs. (Levin, N., et al., 2024)

Advantages of Low-Input & Rapid TIL Isolation and Expansion

Accelerated Immunotherapy Evaluation

Utilize low-input samples for rapid expansion of functional TILs. This enables efficient screening of novel agents (immuno-oncology drugs, small molecule inhibitors, cytokines, oncolytic viruses) or combination therapies on critical TIL functions – including activation, proliferation, cytotoxic killing, and reversal of exhaustion – significantly shortening candidate therapy assessment timelines.

In-Depth Tumor Immune Microenvironment Profiling

Overcome tissue limitations to efficiently isolate TILs from minimal samples. Supports advanced analyses like single-cell multi-omics sequencing (RNA/DNA/TCR) and deep immunophenotyping, enabling precise characterization of TME heterogeneity, T-cell clonal dynamics, and functional states to aid biomarker discovery and validation.

Empowering Translational Research & Complex Model Studies

Facilitates rapid analysis of TIL dynamics using precious clinical biopsy specimens (e.g., pre/post-treatment pairs), providing insights for clinical translation. Offers feasible TIL research solutions for complex preclinical models like PDX or humanized mice, where tissue availability is constrained.

Our Services

Alfa-TIL^TM provides a streamlined, fast, and scalable TIL isolation and expansion service. Our platform is designed to maximize TIL recovery from small tumor specimens, reducing the time required to generate usable TIL populations.

TIL Low-Input Isolation Service

Efficient tumor-infiltrating lymphocyte (TIL) isolation from diverse solid tumor tissues, including murine tumor models, human tumor samples, and PDX specimens. The protocol is optimized for minimal starting material, enabling robust TIL recovery even from highly restricted tissue biopsies in early-stage research.

TIL Rapid Expansion Service

Leveraging a refined expansion platform, this service delivers scalable quantities of functional TIL within a compressed timeline. Expanded cells are immediately compatible with in vitro functional assays and in vivo efficacy studies, providing flexible scale-up and predictable scheduling for downstream applications.

Comparison of Traditional vs. Low-Input Rapid TIL Isolation

	Traditional Methods	Alfa-TIL^TM Methods
Tumor Tissue Requirement	Large resected tumor	Metastatic or Unresectable Melanoma
Expansion Time	3–5 weeks	Typically, 10–14 days
Culture Complexity	Multi-step, feeder-dependent, cytokine-heavy	Streamlined, standardized, preclinical-ready
Sample Compatibility	Mostly human surgical samples	Compatible with PDX, xenografts, murine tumors

Key Features of Our Service

Low Tissue Requirements: Capable of isolating TILs from minimal tumor samples, ideal for rare or difficult-to-obtain tumor types.
Rapid Expansion: We utilize advanced techniques to expand TILs efficiently, reducing culture time and speeding up the development timeline.
High-Quality TILs: Ensuring high viability and tumor-reactivity, essential for downstream applications like functional validation and genetic enhancement.

Alfa-TIL^TM supports immuno-oncology research teams with fast, flexible, and sample-sparing TIL isolation solutions. Whether working with limited tumor tissue or compressed project timelines, the low-input Alfa-TIL™ platform enables consistent, high-quality TIL output for preclinical studies. Contact us to discuss your project needs and explore how our TIL development services can accelerate your pipeline.

Reference

Levin, N., et al. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes. Journal for immunotherapy of cancer. 2024, 12(5): e008645.

For research use only.